- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05846035
Paraneoplastic Syndrome in Hepatocellular Carcinoma Patients
April 26, 2023 updated by: Hala Maher Abdelhafiz, Sohag University
Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world with rising incidence.
Globally, there has been substantial variation in prevalence of risk factors for HCC over years, like control of viral hepatitis in developing countries but growing epidemic of fatty liver disease in developed world.
Changing epidemiology of HCC is related to trends in these risk factors, Paraneoplastic syndromes (PNS) are defined as systemic, metabolic, or other distant consequences of malignancy resulting, either directly or indirectly, from production by the neoplasm of substances that gain access to the blood stream, thereby exerting their effects on distant organs or tissues There is four major HCC-associated paraneoplastic syndromes among Cirrhotic patients,i.e.hypercholesterolemia,hypoglycemia,hypercalcemia,and erythrocytosis .
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
80
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hala M Abdelhafeez, Resident
- Phone Number: 01027319657
- Email: halamaher@med.sohag.edu.eg
Study Contact Backup
- Name: Amr M Zaghloul, Assistant professor
Study Locations
-
-
-
Sohag, Egypt
- Recruiting
- Sohag University hospitals
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
- Cirrhotic Patients with HCC.
- HCC will be diagnosed based on Alpha -feto protein (AFP) and dynamic imaging.
Description
Inclusion Criteria:
- - Cirrhotic Patients with HCC.
- HCC will be diagnosed based on Alpha -feto protein (AFP) and dynamic imaging.
Exclusion Criteria:
- - Patient known to have primary parathyroid disease, patients with bone metastasis or excessive use of antacids.
- Patients with secondary polycythemia (as chronic hypoxia) and patients with polycythemia rubra vera.
- Patients with acute infections or GIT bleeding.
- Patients with preexisting dyslipidemia.
- Patients with significant cholestasis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the prevalence of Paraneoplastic Syndrome in cirrhotic Patients with HCC.
Time Frame: 12 months
|
To investigate the prevalence of PNS (hypoglycemia, hypercholesterolemia, hypercalcemia, erythrocytosis, and thrombocytosis) and clinical characteristics in cirrhotic Patients with HCC.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology. 2022 Jul;304(1):228-237. doi: 10.1148/radiol.212426. Epub 2022 Apr 12.
- Qu Q, Wang S, Chen S, Zhou L, Rui JA. Prognostic role and significance of paraneoplastic syndromes in hepatocellular carcinoma. Am Surg. 2014 Feb;80(2):191-6.
- Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol. 2021 Jul;12(Suppl 2):S361-S373. doi: 10.21037/jgo.2020.02.08.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 15, 2023
Primary Completion (Anticipated)
April 30, 2024
Study Completion (Anticipated)
April 30, 2024
Study Registration Dates
First Submitted
April 26, 2023
First Submitted That Met QC Criteria
April 26, 2023
First Posted (Estimate)
May 5, 2023
Study Record Updates
Last Update Posted (Estimate)
May 5, 2023
Last Update Submitted That Met QC Criteria
April 26, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Soh-Med-23-04-12MS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma Patients
-
University of MilanUnknownOverall Survival | Patients Affected by Hepatocellular Carcinoma | Disease-Free SurvivalItaly
-
Hospices Civils de LyonCompletedPatients Eligible to a Curative Treatment for Primary HCCFrance
-
Cancer Institute and Hospital, Chinese Academy...RecruitingPatients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or MetastasiChina
-
Chinese University of Hong KongRecruitingConfirmed Diagnosis of Hepatocellular Carcinoma | Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery | Child's A to C CirrhosisHong Kong
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingAdjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
Clinical Trials on Triphasic C.T abdomen and pelvis
-
Ontario Clinical Oncology Group (OCOG)Ontario Ministry of Health and Long Term CareCompletedAdenocarcinoma | Cervical Cancer | Squamous Cell Carcinoma | Adenosquamous CarcinomaCanada
-
Yeovil District Hospital NHS Foundation TrustUniversity of Southampton; University Hospital Southampton NHS Foundation Trust and other collaboratorsUnknownEmergencies | Frail Elderly Syndrome | Sarcopenia | SurgeryUnited Kingdom
-
Ottawa Hospital Research InstituteCompletedDeep Vein Thrombosis | Venous Thromboembolism | Pulmonary EmbolismCanada
-
Indiana UniversityCompletedKidney StonesUnited States
-
The Netherlands Cancer InstituteZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingMRI | Colorectal Cancer | Peritoneal CarcinomatosisNetherlands
-
Peking Union Medical College HospitalRecruiting
-
Sahlgrenska University Hospital, SwedenCompletedRectal Cancer | Liver MetastasesSweden
-
Centre Hospitalier Universitaire de NīmesRecruitingCerebral Palsy InfantileFrance
-
Cho-yu Chan, MDCompletedBradycardia | HypoxemiaTaiwan